FAST NEWS: Hillhouse invests $22 million in Legend Biotech
The latest: Genscript Biotech Corp. (1548.HK) announced on Sunday that its New York-listed subsidiary Legend Biotech Corp. (LEGN.US) has sold 692,782 shares through a private placement to LGN Holdings Ltd.,…
FAST NEWS: Legend Biotech to raise $300 million from share sale
The latest: Genscript Biotech Corp. (1548.HK) announced Monday that its New York-listed subsidiary Legend Biotech Corp. (LEGN.US) will sell about 5.5 million new American Depositary Shares (ADSs) to an entity advised by…
Genscript Bio Gets Booster from Subsidiary’s New Cancer Drug
The company’s Legend Biotech unit has found recent success with Carvykti, a chimeric antigen receptor T-cell (CAR-T) therapy, which earned $134 million in its first nine months on the marketKey…
FAST NEWS: Legend Biotech Plans $250 Million ADS Public Offering
The latest: Genscript Biotech Corp. (1548.HK) announced its New York-listed subsidiary, Legend Biotech Corp. (LEGN.US), plans to conduct a public offering of $250 million worth of American Depository Shares (ADS).…
GenScript Losses Widen, But Investors Focus on Newly Approved Cancer Treatment
Company expects to lose up to $519 million last year, but its fortunes may improve after its Legend Biotech unit received FDA approval this week for a new CAR-T cell…
Recent Articles
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Sunshine tries out asset leasing as insurance demand cools
6963.HK 3396.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
BRIEF: Tencent invests in major new Ubisoft unit
0700.HK UBI.PA
-
ZG Group set to forge Hong Kong’s second De-SPAC listing
2572.HK
